Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation

References

• Eapen ZJ , Mi X , Qualls LG , et al. Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. J Card Fail. 2014;20:23–30.
   PubMed Web of Science ®Google Scholar
• Ageno W , Gallus AS , Wittkowsky A , et al., American College of Chest P . Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College Of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–88S.
   PubMed Web of Science ®Google Scholar
• Skeppholm M , Friberg L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Card. 2014;103:998–1005.
   PubMed Web of Science ®Google Scholar
• Molteni M , Cimminiello C. Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. Thromb J. 2014;12:5.
   PubMedGoogle Scholar
• Connolly SJ , Ezekowitz MD , Yusuf S , et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR , Mahaffey KW , Garg J , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB , Alexander JH , McMurray JJ , et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP , Ruff CT , Braunwald E , et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Ruff CT , Giugliano RP , Braunwald E , et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Heidbuchel H , Verhamme P , Alings M , et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507.
   PubMed Web of Science ®Google Scholar
• Watson T , Shantsila E , Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373:155–166.
   PubMed Web of Science ®Google Scholar
• Weitz JI , Connolly SJ , Patel I , et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633–641.
   PubMed Web of Science ®Google Scholar
• Salazar DE , Mendell J , Kastrissios H , et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107:925–936.
   PubMed Web of Science ®Google Scholar
• Agnelli G , Gallus A , Goldhaber SZ , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180–187.
   PubMed Web of Science ®Google Scholar
• Raghavan N , Frost CE , Yu Z , et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81.
   PubMed Web of Science ®Google Scholar
• Stangier J , Rathgen K , Stahle H , et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.
   PubMed Web of Science ®Google Scholar
• Ogata K , Mendell-Harary J , Tachibana M , et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743–753.
   PubMed Web of Science ®Google Scholar
• Kubitza D , Becka M , Roth A , et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008;24:2757–2765.
   PubMed Web of Science ®Google Scholar
• Eriksson BI , Dahl OE , Buller HR , et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemostasis. 2005;3:103–111.
   PubMed Web of Science ®Google Scholar
• Mega JL , Braunwald E , Mohanavelu S , et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29–38.
   PubMed Web of Science ®Google Scholar
• Investigators E , Bauersachs R , Berkowitz SD , et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510.
   PubMed Web of Science ®Google Scholar
• Investigators E-P , Buller HR , Prins MH , et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–1297.
   PubMed Web of Science ®Google Scholar
• EMC . Xarelto 2.5 mg film-coated tablets SPC. Accessed 2017 Jun 12 . Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
   Google Scholar
• ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340–7 e1.
   PubMed Web of Science ®Google Scholar
• Lassen MR , Davidson BL , Gallus A , et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemostasis. 2007;5:2368–2375.
   PubMed Web of Science ®Google Scholar
• Apostolakis S , Alexander JH , Becker RC , et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–2885.
   PubMed Web of Science ®Google Scholar
• Alexander JH , Lopes RD , James S , et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.
   PubMed Web of Science ®Google Scholar
• Connolly SJ , Milling TJ Jr. , Eikelboom JW , et al. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–1141.
   PubMed Web of Science ®Google Scholar
• Cramer JA , Roy A , Burrell A , et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47.
   PubMed Web of Science ®Google Scholar
• Vrijens B , Heidbuchel H . Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17:514–523.
   PubMed Web of Science ®Google Scholar
• Vrijens B , De Geest S , Hughes DA , et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73: 691–705.
   PubMed Web of Science ®Google Scholar
• Bae JP , Dobesh PP , Klepser DG , et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care. 2012;18:139–146.
   PubMed Web of Science ®Google Scholar
• Lane DA , Aguinaga L , Blomstrom-Lundqvist C , et al. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace. 2015;17: 1747–1769.
   PubMed Web of Science ®Google Scholar
• Lahaye S , Regpala S , Lacombe S , et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost. 2014;111: 465–473.
   PubMed Web of Science ®Google Scholar
• Claxton AJ , Cramer J , Pierce C . A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.
   PubMed Web of Science ®Google Scholar
• Laliberte F , Nelson WW , Lefebvre P , et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29:675–690.
   PubMed Web of Science ®Google Scholar
• Laliberte F , Bookhart BK , Nelson WW , et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013;6:213–214.
   PubMedGoogle Scholar
• Coleman CI , Roberts MS , Sobeieraj DM , et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28:669–680.
   PubMed Web of Science ®Google Scholar
• Schulman S , Shortt B , Robinson M , et al. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemostasis. 2013;11: 1295–1299.
   PubMed Web of Science ®Google Scholar
• Tsai K , Erickson SC , Yang J , et al. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care. 2013;19:e325–32.
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A , Skjoth F , Larsen TB , et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemostasis. 2015;13:495–504.
   PubMed Web of Science ®Google Scholar
• Shiore S , Carey EP , Turakhia MP , et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167:810–817.
   PubMed Web of Science ®Google Scholar
• Shore S , Ho PM , Lambert-Kerzner A , et al. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015;313: 1443–1450.
   Google Scholar
• Montalescot G . Adherence and persistence to apixaban treatment in patients with non valvular atrial fibrillation is high and similar with standard of care patient education or with an additional educational program: the randomized AEGEAN study. Circulation. 2016;134:A18842.
   Google Scholar
• Forslund T , Wettermark B , Hjemdahl P . Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72:329–338.
   PubMed Web of Science ®Google Scholar
• McHorney CA , Crivera C , Laliberte F , et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the pharmacy quality alliance measure. Curr Med Res Opin. 2015;31:2167–2173.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J , Ehlken B , Evers T . Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18: 1150–1157.
   PubMed Web of Science ®Google Scholar
• Alberts MJ , Peacock WF , Fields LE , et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. 2016;215: 11–13.
   PubMed Web of Science ®Google Scholar
• Yao X , Abraham NS , Alexander GC , et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2). pii: e003074. doi: 10.1161/JAHA.115.003074.
   Web of Science ®Google Scholar
• Zhou M , Chang HY , Segal JB , et al. Adherence to a novel oral anticoagulant among patients with atrial fibrillation. J Manage Care Specia Phar. 2015;21:1054–1062.
   PubMed Web of Science ®Google Scholar
• Cutler TW , Chuang A , Huynh TD , et al. A retrospective descriptive analysis of patient adherence to dabigatran at a large academic medical center. J Manage Care Specia Phar. 2014;20:1028–1034.
   PubMed Web of Science ®Google Scholar
• Crivera C , Nelson WW , Bookhart B , et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin. 2015;31:1889–1895.
   PubMed Web of Science ®Google Scholar
• Coleman CI , Tangirala M , Evers T . Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. Int J Cardiol. 2016;212: 171–173.
   PubMed Web of Science ®Google Scholar
• Brown JD , Shewale AR , Talbert JC . Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial fibrillation. J Manage Care Specia Phar. 2016;22: 1319–1329.
   PubMedGoogle Scholar
• Coleman C , Yuan Z , Schein J , et al. Importance of balancing follow-up time and impact of oral-anticoagulant users’ selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. Curr Med Res Opin. 2017;33: 1033–1043.
   PubMed Web of Science ®Google Scholar
• Shields AM , Lip GY . Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med. 2015;278:1–18.
   PubMed Web of Science ®Google Scholar
• Raparelli V , Proietti M , Cangemi R , et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117: 209–218.
   PubMed Web of Science ®Google Scholar
• Kimmel SE , Chen Z , Price M , et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med. 2007;167:229–235.
   PubMed Web of Science ®Google Scholar
• Pastori D , Pignatelli P , Saliola M , et al. Inadequate anticoagulation by vitamin K antagonists is associated with major adverse cardiovascular events in patients with atrial fibrillation. Int J Cardiol. 2015;201: 513–516.
   PubMed Web of Science ®Google Scholar
• Proietti M , Lip GY . Major outcomes in atrial fibrillation patients with one risk factor: impact of time in therapeutic range observations from the SPORTIF trials. Am J Med. 2016;129: 1110–1116.
   PubMed Web of Science ®Google Scholar
• Wallentin L , Yusuf S , Ezekowitz MD , et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376: 975–983.
   PubMed Web of Science ®Google Scholar
• Wallentin L , Lopes RD , Hanna M , et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127: 2166–2176.
   PubMed Web of Science ®Google Scholar
• Piccini JP , Hellkamp AS , Lokhnygina Y , et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014;3: e000521.
   PubMed Web of Science ®Google Scholar
• Clarkesmith DE , Pattison HM , Lip GY , et al. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PloS One. 2013;8:e74037.
   PubMed Web of Science ®Google Scholar
• Bancroft T , Lim J , Wang C , et al. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther. 2016;38: 545-56e1-6.
   PubMed Web of Science ®Google Scholar
• Nelson WW , Song X , Coleman CI , et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30: 2461–2469.
   PubMed Web of Science ®Google Scholar
• Martinez C , Katholing A , Wallenhorst C , et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemostasis. 2016;115:31–39.
   PubMed Web of Science ®Google Scholar
• Zalesak M , Siu K , Francis K , et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Quality Outcomes. 2013;6: 567–574.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J , Ebertz F , Forster K , et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC registry. Thromb Haemostasis. 2015;113:1247–1257.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J , Forster K , Ebertz F , et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17:530–538.
   PubMed Web of Science ®Google Scholar
• Nelson WW , Song X , Thomson E , et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;31:1831–1840.
   PubMed Web of Science ®Google Scholar
• Clemens A , Haertter S , Friedman J , et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin. 2012;28:195–201.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J , Gelbricht V , Forster K , et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35: 1888–1896.
   PubMed Web of Science ®Google Scholar
• Mar PL , Familtsev D , Ezekowitz MD , et al. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and procedures. Int J Cardiol. 2016;202: 578–585.
   PubMed Web of Science ®Google Scholar
• Rubboli A . Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter? Curr Med Res Opin. 2015;31:1845–1847.
   PubMed Web of Science ®Google Scholar